PFE Pfizer Inc

   By Dave Sebastian 
 

Pfizer Inc. and BioNTech SE said they have proposed to supply 200 million doses of their Covid-19 vaccine candidate to the European Union, with deliveries starting by the end of this year.

EU member states would have the option to add an additional 100 million doses of their investigational BNT162 mRNA-based vaccine candidate, the companies said Wednesday.

Pfizer and BioNTech said they are entering contract negotiations with the European Commission. They said the proposed supply agreement would represent the largest initial order of vaccine doses for both companies to date.

The companies said they would make vaccine doses for Europe at BioNTech's German manufacturing sites and Pfizer's manufacturing site in Belgium. If the supply proposal is approved, the European Commission would lead the dose allocation among its 27 members, Pfizer and BioNTech said.

"We have activated our supply chain, most importantly our site in Belgium, and are starting to manufacture so that our vaccine would be available as soon as possible, if our clinical trials prove successful and regulatory approval is granted," Pfizer Chairman and Chief Executive Albert Bourla said.

The companies said they are also interested in possibly supplying the vaccine candidate to the COVAX Facility, a mechanism co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations and the World Health Organization that aims to provide governments with access to Covid-19 vaccine candidates.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

September 09, 2020 06:52 ET (10:52 GMT)

Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024

Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024